Clinical Trial: ALLIANCE A071702

ALLIANCE A071702

Status: Closed

A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent WHO Grade 4 Glioma

A071702 is closed to accrual, effective June 2, 2025.